Professor Wingren is in addition to his role as CTO at Immunovia a lecturer at the Dept. of Immunotechnology within CREATE Health Translational Cancer Center at Lund University, Sweden. Professor Wingren directs a research group working on the development of recombinant antibody microarrays for high-throughput disease proteomics (“unlocking biomarker discovery”), the Immunovia platform, with a particular focus on oncoproteomics and autoimmunity. The research is conducted in a translational manner, going from the bed-to-bench and back again, with the goal to define serum, plasma, and urine biomarkers for disease diagnosis, prognosis, and classification. In 2014, he was promoted to Professor in Immunotechnology. Prior to joining Immunotechnology in 1999, Dr. Wingren pursued his post-doctoral training in structural biology in the laboratory of Prof. Ian Wilson at the Scripps Research Institute, La Jolla, USA (1997-1999). Dr. Wingren received his Ph.D. in biochemistry at Lund University in 1997, and a B.Sc. in chemistry in 1991.
Haematology